The diagnostic performance of classical molecular tests used for detecting human papillomavirus
Cervical samples were evaluated for human papillomavirus (HPV) presence using the hybrid capture-2 (HC2) assay and the polymerase chain reaction (PCR) with three different primer sets (GP5+/6+, MY09/11 and pU1M/2R). PCR results were compared to HC2 and results of all assays were compared to cytologi...
- Autores:
- Tipo de recurso:
- Fecha de publicación:
- 2012
- Institución:
- Universidad del Rosario
- Repositorio:
- Repositorio EdocUR - U. Rosario
- Idioma:
- eng
- OAI Identifier:
- oai:repository.urosario.edu.co:10336/22494
- Acceso en línea:
- https://doi.org/10.1016/j.jviromet.2012.05.023
https://repository.urosario.edu.co/handle/10336/22494
- Palabra clave:
- Virus DNA
Abnormal laboratory result
Adolescent
Adult
Analytic method
Article
Cancer screening
Colposcopy
Controlled study
Disease course
Female
High risk population
Human
Human cell
Hybrid capture assay 2
Intermethod comparison
Nonhuman
Papanicolaou test
Polymerase chain reaction
Post test probability
Priority journal
Statistical parameters
Uterine cervix cancer
Uterine cervix cytology
Virus detection
Virus DNA cell DNA interaction
Wart virus
Adult
Cervix Uteri
Colposcopy
Cytological Techniques
Female
Humans
Molecular Diagnostic Techniques
Nucleic Acid Hybridization
Papillomaviridae
Papillomavirus Infections
Polymerase Chain Reaction
Prevalence
Sensitivity and Specificity
Virology
Young Adult
Human papillomavirus
Human papillomavirus
Hybrid capture assay 2
Polymerase chain reaction
Screening
Test performance
- Rights
- License
- Abierto (Texto Completo)
Summary: | Cervical samples were evaluated for human papillomavirus (HPV) presence using the hybrid capture-2 (HC2) assay and the polymerase chain reaction (PCR) with three different primer sets (GP5+/6+, MY09/11 and pU1M/2R). PCR results were compared to HC2 and results of all assays were compared to cytological and colposcopy findings. Post-test probability was assessed in individual assays and test combinations. HPV-DNA prevalence was 36.5% with HC2 and 55.2% with PCR. MY09/11 detected HPV-DNA in 38% of samples, GP5+/6+ in 19.1% and pU1M/2R in 16.4%. pU1M/2R and HC2 had the highest concordance (75.31%, k= 0.39 in the whole population; 74.1%, k= 0.5 in women with abnormal cytology). pU1M/2R had the best diagnostic performance, including optimal post-test probabilities and cervical abnormality detection (individually or in a panel of tests). Women positive for pU1M/2R may be at higher risk of disease progression; the assay performance when combined with a Pap smear in cervical cancer screening programs should be evaluated. © 2012 Elsevier B.V.. |
---|